Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Jade Biosciences, Inc. (NASDAQ:JBIO) have earned a consensus rating of “Moderate Buy” from the five research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $19.00.

Several equities research analysts recently weighed in on JBIO shares. Jefferies Financial Group started coverage on shares of Jade Biosciences in a research note on Monday, July 14th. They set a “buy” rating and a $16.00 price objective on the stock. Wall Street Zen lowered shares of Jade Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 16th. BTIG Research started coverage on shares of Jade Biosciences in a research note on Thursday. They set a “buy” rating and a $28.00 price objective on the stock. Weiss Ratings reiterated a “sell (e-)” rating on shares of Jade Biosciences in a research note on Wednesday, October 8th. Finally, Wedbush raised their price target on shares of Jade Biosciences from $17.00 to $18.00 and gave the company an “outperform” rating in a research note on Thursday, August 14th.

Institutional Investors Weigh In On Jade Biosciences

Several large investors have recently made changes to their positions in JBIO. Deltec Asset Management LLC acquired a new stake in shares of Jade Biosciences in the second quarter valued at approximately $157,000. Geode Capital Management LLC acquired a new stake in shares of Jade Biosciences in the second quarter valued at approximately $6,759,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Jade Biosciences in the second quarter valued at approximately $71,000. Intech Investment Management LLC acquired a new stake in shares of Jade Biosciences in the second quarter valued at approximately $230,000. Finally, Versant Venture Management LLC acquired a new stake in shares of Jade Biosciences in the second quarter valued at approximately $15,243,000.

Jade Biosciences Trading Up 0.1%

JBIO opened at $9.09 on Thursday. The firm has a market capitalization of $296.61 million, a price-to-earnings ratio of -0.30 and a beta of 1.05. Jade Biosciences has a fifty-two week low of $6.57 and a fifty-two week high of $105.00. The stock’s 50-day simple moving average is $7.91.

Jade Biosciences (NASDAQ:JBIO) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.43).

About Jade Biosciences

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.